



Divi's Laboratories Limited

Regd. Office: 1-72/23(P)/DIVIS/303, Divi Towers, Cyber Hills, Gachibowli, Hyderabad - 500032. CIN: L24110TG1990PLC011854
Phone: 040-23786300 Fax: 040-23786460 email: mail@divislabs.com website: www.divislabs.com

STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2017

(₹ in Lakhs)

Particulars	STANDALONE					
	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
	31.12.2017 (Unaudited)	30.09.2017 (Unaudited)	31.12.2016 (Unaudited)	31.12.2017 (Unaudited)	31.12.2016 (Unaudited)	31.03.2017 (Audited)
Total Income from operations	105489	92379	99819	281359	305415	414175
Net Profit / (Loss) for the period (before Tax and Exceptional items)	30550	27611	36788	82331	103778	138823
Net Profit / (Loss) for the period before tax (after Exceptional items)	30550	27611	36788	82331	103778	138823
Net Profit / (Loss) for the period after tax (after Exceptional items)	22466	20678	26832	60798	79398	105327
Total Comprehensive Income for the period [comprising Profit/ (Loss) for the period (after tax)] and Other Comprehensive Income (after tax)]	22429	20640	26802	60687	79238	105187
Equity Share Capital	5309	5309	5309	5309	5309	5309
Reserves (excluding Revaluation Reserve as shown in the Audited Balance Sheet of the previous year)						535582
Earnings Per Share (of ₹ 2/- each) (not annualised) Basic & Diluted (₹)	8.46	7.79	10.11	22.90	29.91	39.68

Notes:

- The above is an extract of the detailed format of Un-audited Financial Results for the quarter and nine months ended 31st December 2017 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015. The full format of the Un-audited Financial Results for the quarter and nine months ended 31st December, 2017 are available on the Websites of Stock Exchanges (www.bseindia.com and www.nseindia.com) and also available on the Company's website www.divislabs.com.
- These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The company's Unit-II at Visakhapatnam was inspected by the US-FDA from 11th September 2017 to 19th September 2017. US-FDA has issued Establishment Inspection Report (EIR) for the same.
- Post implementation of Goods and Service Tax (GST) effective from 1st July, 2017, revenue is reported net of GST as per Ind AS 18. Revenue, however, is reported inclusive of excise duty for the current and previous periods. Had the previously reported revenue been shown net of excise duty, comparative revenue of the company would have been as under:

(₹ in Lakhs)

	Quarter ended			Nine Months ended		Year ended
	31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016	31.03.2017
Revenue from operations (net of excise duty)	103788	88752	96305	273803	296531	402386

for Divi's Laboratories Limited

Dr. Murali K. Divi
Chairman & Managing Director

Place : Hyderabad
Date : 27.01.2018

Size: 16x14 Cms